MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome (12S ribosomal RNA gene). It activates AMPK signaling and modulates metabolic adaptation, which is why research literature sometimes describes it as an exercise-mimetic compound. It was first characterized in 2015; most published research is preclinical.
Research notes
What MOTS-c benefits are reported in the literature
The published research on MOTS-c clusters around four observation categories. None of these constitute clinical claims — most data is preclinical or early-translational — but the literature read is consistent across multiple research groups.
Metabolic and mitochondrial function. The original characterization (Lee et al., Cell Metabolism 2015) reported that MOTS-c administration in mouse models improved insulin sensitivity, increased glucose uptake in skeletal muscle, and reduced age-associated insulin resistance. The mechanism centers on AMPK activation, which downstream affects mitochondrial biogenesis and substrate utilization. Subsequent work has reinforced the AMPK pathway as the primary signaling node.
Insulin sensitivity and glucose regulation. Multiple rodent studies report that exogenous MOTS-c administration improves glucose tolerance in diet-induced obesity and aging models. The 2015 Cell Metabolism paper specifically documented enhanced glucose disposal in skeletal muscle and reduced hepatic glucose production. Human data is limited; circulating MOTS-c levels have been reported to decline with age and to associate with metabolic-syndrome markers in observational cohorts.
Exercise performance and adaptation. MOTS-c is sometimes described in research literature as an exercise-mimetic compound because the signaling pattern it activates (AMPK, PGC-1α downstream) overlaps with the pathways exercise activates. Rodent studies have reported increased running capacity and reduced exercise-induced fatigue with MOTS-c administration. Direct human-performance trials are not yet published, and the exercise-mimetic framing should be read as a mechanism observation, not a parity claim.
Longevity and age-associated decline context. MOTS-c sits in the broader mitochondrial-derived-peptide research category alongside humanin and SHLP family peptides. The longevity framing comes from the observation that circulating levels decline with age and that exogenous administration partially reverses age-associated metabolic phenotypes in mouse models. The translational gap to human longevity outcomes is wide; the data point is interesting, not actionable.
The literature is preclinical-dominant. No FDA-approved indication exists, no large-scale human trials have read out, and the long-term safety profile in humans is not characterized.
How does MOTS-c work?
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome — specifically in the 12S ribosomal RNA gene. This makes it structurally unusual: most peptides we cover are encoded in nuclear DNA. MOTS-c was discovered in 2015 and has been characterized as a regulator of cellular metabolism and stress response.
The published mechanism centers on AMPK signaling activation. AMPK is the cellular energy sensor that gets activated by exercise, fasting, and metabolic stress. MOTS-c administration produces a similar signaling pattern — which is why the compound is sometimes called an "exercise mimetic" in research literature, although the comparison should be read carefully.
Other reported mechanisms include glucose-uptake regulation in muscle tissue and modulation of the folate–methionine cycle. The full pathway map is still being characterized.
What doses are used in research?
Published preclinical and limited human research uses doses in the 5–15 mg subcutaneous range. Common research-protocol patterns:
- 5–10 mg daily for 2–4 weeks
- 10–15 mg every other day for longer cycles
- Cycling is universal — the compound is not used as a continuous protocol in published literature
Half-life data is limited but downstream effects (AMPK activation, glucose-uptake changes) persist for many hours after administration.
What are the known side-effect concerns?
The published side-effect profile in research-protocol literature is mild compared to growth-hormone-axis compounds. Most-reported observations:
- Mild fatigue in the first few days of a new cycle
- Injection-site reactions at higher doses
- No reported metabolic disruption in published short-cycle protocols
What does this guide cover?
MOTS-c is a structurally compact peptide (16 amino acids) that's relatively straightforward to synthesize cleanly, so HPLC purity figures from disciplined vendors tend to cluster tightly. Our vendor audits weight identity confirmation more heavily than purity for this compound — the smaller molecule means fewer truncation impurities, but identity-confirmation matters because the sequence is unusual.
Is MOTS-c legal after the July 2026 FDA vote?
Update, 29 October 2026: HHS filed an interim enforcement-discretion policy (Federal Register, 30 October). It says HHS does not intend to act against 503A pharmacies and physicians compounding MOTS-c acetate for subcutaneous or intramuscular injection. The conditions include a patient-specific prescription, a single ingredient and API from a registered manufacturer. The policy is not a rule and does not cover research-use-only vials. Our HHS policy explainer lists all ten conditions.
No. On 23 July 2026 the FDA Pharmacy Compounding Advisory Committee voted 7-5 with two abstentions to recommend MOTS-c for the 503A Bulks List, nominated for obesity and osteoporosis. It had already been removed from the Category 2 do-not-compound list in April 2026.
Neither step makes compounding lawful. Category 2 removal does not confer eligibility, and an advisory recommendation is not a rule. FDA must complete notice-and-comment rulemaking or grant interim Category 1 status, and its own review scientists recommended against all seven peptides on that agenda. The mechanics are in our FDA peptide vote explainer.
Nothing about the vote changes the legal status of research-grade MOTS-c sold online.
What the third-party testing shows
Across 85 MOTS-c certificates issued by Kovera Labs, covering 63 vendors, certified between 8 February and 4 June 2026 and retrieved from Kovera's verifier on 2 August 2026:
| Measure | Value |
|---|---|
| Records | 85 |
| Distinct vendors | 63 |
| Median purity | 99.92% |
| Lowest purity | 98.55% |
| Records below 98% | 0 |
| Identity confirmation failures | 0 |
| Vials under 90% of labelled content | 0 |
In this Kovera set no vial fell below 98% purity or under 90% of its labelled content; four measured between 94.7% and 98.9% of label. Our wider pooled record, which adds Janoshik and vendor-published sets, has one MOTS-c vial under 90% of label out of 90 with a measured content. The compact 16-residue sequence is straightforward to synthesise cleanly, and the data reflects that.
A certificate covers the batch that was tested rather than your vial, so the lot numbers have to match, and Kovera revises certificates in place under the same reference number. Note the date you retrieved one, and check it against the issuing lab through our COA verifier.
Is MOTS-c in human clinical trials?
Not MOTS-c itself. The one industry trial was CohBar's CB4211, a modified MOTS-c analogue, tested in an 88-person Phase 1a/1b in fatty liver disease and completed in 2021 with no results posted. A Phase 2 "MOTS-c for prediabetes" record (NCT07505745) is one of eight registrations from a single sponsor whose siblings describe themselves as fictional. Status as of 13 October 2026.
Related reading
- FDA peptide vote 2026 - the full vote breakdown and the gates still standing between a recommendation and legal compounding.
- Epitalon - recommended at the same meeting, from a different research tradition.
- Semax and KPV - the other compounds backed by the committee, with their own testing records.
- Klotho - the other mitochondrial and longevity-adjacent target we track.
- Longevity peptides 2026 - where MOTS-c sits in the broader cluster.
- What 1,828 Kovera COAs show - the corpus behind the figures above.
What it's researched for
- mitochondrial function
- exercise-response research
- metabolic regulation
Where to source it
ALL 19 VENDORS →RANKED BY COMPOSITE SCORE · PRICES ARE SNAPSHOTS FROM THE PRICE INDEX · PER-MG IS A WITHIN-COMPOUND COMPARATOR
Frequently asked about MOTS-c
What is MOTS-c?
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome — specifically in the 12S ribosomal RNA gene. This makes it structurally unusual: most peptides are encoded in nuclear DNA. It was discovered in 2015 and is studied as a regulator of cellular metabolism and stress response.
How does MOTS-c work?
Published research centers on AMPK signaling activation. AMPK is the cellular energy sensor that gets activated by exercise, fasting, and metabolic stress; MOTS-c administration produces a similar signaling pattern in rodent and cell-culture models. The exercise-mimetic framing should be read carefully — direct parity with actual training is not established.
Is MOTS-c FDA-approved?
No. MOTS-c is not approved by the FDA, EMA, or any regulator for any indication. All current research is preclinical or early-translational. It is sold only as research-grade material.
What doses are used in MOTS-c research?
Published research literature cites 5–15 mg subcutaneous in cycles of 2–8 weeks. The half-life is not fully characterized, though multi-hour systemic effects have been observed in animal studies.
What is the typical purity of research-grade MOTS-c?
In the 2,087-result lab record behind our [purity study](/articles/peptide-purity-fill-2087-lab-results) (Kovera, Janoshik and four vendor-published sets, duplicates counted once), MOTS-c has 92 results from 65 clients. Median HPLC purity was 99.90% and the lowest 97.60%. Of 90 results with a measured content, 1 held under 90% of label; the median was 109.6%. None failed identity. That short vial is outside Kovera: the 85 Kovera certificates broken down further down this page include none under 90% of label. These are results vendors chose to publish, not a random sample.